Beth Israel Deaconess Medical Center, a Framingham biotechnology company, and an international research group are joining in a research initiative aimed at improving the diagnosis and treatment for one of the deadliest forms of cancer. James Moser, associate professor of surgery at Beth Israel Deaconess Medical Center, is quoted.
